Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Candel Therapeutics Inc (CADL)

Candel Therapeutics Inc (CADL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 179,726
  • Shares Outstanding, K 29,756
  • Annual Sales, $ 0 K
  • Annual Income, $ -37,940 K
  • 60-Month Beta -0.84
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 32.99
Trade CADL with:

Options Overview Details

View History
  • Implied Volatility 88.49% ( +33.03%)
  • Historical Volatility 153.61%
  • IV Percentile 13%
  • IV Rank 21.81%
  • IV High 384.07% on 04/18/24
  • IV Low 6.03% on 04/15/24
  • Put/Call Vol Ratio 0.85
  • Today's Volume 100
  • Volume Avg (30-Day) 349
  • Put/Call OI Ratio 0.31
  • Today's Open Interest 12,506
  • Open Int (30-Day) 11,028

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.33
  • Growth Rate Est. (year over year) +302,827.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.78 +4.50%
on 06/21/24
12.41 -51.32%
on 05/22/24
-6.23 (-50.77%)
since 05/21/24
3-Month
1.42 +325.35%
on 03/22/24
14.30 -57.76%
on 05/16/24
+4.59 (+316.55%)
since 03/21/24
52-Week
0.66 +815.15%
on 11/03/23
14.30 -57.76%
on 05/16/24
+4.74 (+364.62%)
since 06/21/23

Most Recent Stories

More News
Pancreatic Cancer on the Rise: How Biotech Firms are Developing Groundbreaking Treatments

/CNW/ -- After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may...

RHHBY : 35.5900 (+1.05%)
ONCY : 1.0100 (+1.45%)
VSTM : 3.16 (-2.77%)
CADL : 6.04 (+1.00%)
FGEN : 1.1300 (+2.73%)
REGN : 1,053.14 (+0.84%)
ONC.TO : 1.37 (+0.74%)
The Fight Against Pancreatic Cancer: Biotech Firms Develop New Solutions for Rising Gen X Cases

USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovered that Generation X may be experiencing larger per-capita...

ONCY : 1.0100 (+1.45%)
ONC.TO : 1.37 (+0.74%)
RHHBY : 35.5900 (+1.05%)
VSTM : 3.16 (-2.77%)
CADL : 6.04 (+1.00%)
FGEN : 1.1300 (+2.73%)
REGN : 1,053.14 (+0.84%)
Pancreatic Cancer Battle Intensifies: Biotech Innovations Aim to Boost Survival Rates

/CNW/ -- USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic...

ONCY : 1.0100 (+1.45%)
CADL : 6.04 (+1.00%)
AZN : 78.88 (+0.41%)
MRUS : 54.84 (+1.67%)
LTRN : 4.15 (-6.53%)
ONC.TO : 1.37 (+0.74%)
Biotech Developers Pioneer New Treatments, Aiming to Reduce Pancreatic Cancer Fatalities in 2024

USA News Group – Known as one of the deadliest cancers, researchers are working diligently to help increase the chance of survival for pancreatic cancer patients through earlier detection, as according...

ONCY : 1.0100 (+1.45%)
ONC.TO : 1.37 (+0.74%)
CADL : 6.04 (+1.00%)
AZN : 78.88 (+0.41%)
MRUS : 54.84 (+1.67%)
LTRN : 4.15 (-6.53%)
Biotech Companies Making Strides in Pancreatic Cancer Treatment and Early Detection

/CNW/ -- USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can...

ONCY : 1.0100 (+1.45%)
CADL : 6.04 (+1.00%)
ABVC : 0.7130 (-2.99%)
CTMX : 1.2900 (+0.78%)
AMGN : 308.16 (-0.56%)
ONC.TO : 1.37 (+0.74%)
Biotech Innovations Drive Hope in Global Fight Against Pancreatic Cancer

USA News Group – Hope is rising in the fight against one of the deadliest cancers in the world, as a new study recently claimed that a blood test can accurately detect early-stage pancreatic cancer with...

ONCY : 1.0100 (+1.45%)
ONC.TO : 1.37 (+0.74%)
CADL : 6.04 (+1.00%)
ABVC : 0.7130 (-2.99%)
CTMX : 1.2900 (+0.78%)
AMGN : 308.16 (-0.56%)
Biotech Innovations Surge as Global Cancer Diagnosis Rates Continue to Climb

/CNW/ -- In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding...

ONCY : 1.0100 (+1.45%)
CADL : 6.04 (+1.00%)
AZN : 78.88 (+0.41%)
HALO : 51.55 (+1.36%)
JANX : 40.96 (+1.64%)
ONC.TO : 1.37 (+0.74%)
Rising Cancer Rates Drive Biotech Advancements Despite Political Hurdles

USA News Group – In the fight against cancer, a political stumbling block was recently put in place by the US Congress after it voted against the renewal of funding for President Biden’s “Cancer...

ONCY : 1.0100 (+1.45%)
ONC.TO : 1.37 (+0.74%)
CADL : 6.04 (+1.00%)
AZN : 78.88 (+0.41%)
HALO : 51.55 (+1.36%)
JANX : 40.96 (+1.64%)
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market – A Race Worth

EQNX::TICKER_START (ONASDAQ:ONCY),(TSX:ONC),(NASDAQ:BLRX),(NASDAQ:IMRX),(NASDAQ:CADL) EQNX::TICKER_END

ONCY : 1.0100 (+1.45%)
ONC.TO : 1.37 (+0.74%)
BLRX : 0.5900 (unch)
IMRX : 1.4300 (+1.42%)
CADL : 6.04 (+1.00%)
Candel Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

NEEDHAM, Mass., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a late clinical stage...

CADL : 6.04 (+1.00%)

Business Summary

Candel Therapeutics Inc. is a late clinical stage biopharmaceutical company. It involved in developing novel oncolytic viral immunotherapies. The company's product pipeline includes CAN-2409 and CAN-3110. Candel Therapeutics Inc. is based in NEEDHAM, Mass.

See More

Key Turning Points

3rd Resistance Point 6.49
2nd Resistance Point 6.29
1st Resistance Point 6.17
Last Price 6.04
1st Support Level 5.85
2nd Support Level 5.65
3rd Support Level 5.53

See More

52-Week High 14.30
Fibonacci 61.8% 9.09
Fibonacci 50% 7.48
Last Price 6.04
Fibonacci 38.2% 5.87
52-Week Low 0.66

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar